Association of BRAF V600E/K mutation status and prior BRAF/MEK inhibition with pembrolizumab outcomes in advanced melanoma: Pooled analysis of 3 clinical trials
Source: MDLinx, August 2020
Researchers conducted this post hoc analysis of 3 randomized clinical trials (KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006) to explore the correlation of BRAF wild-type (WT) or BRAF V600E/K-mutant status and BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi) therapy with the response to pembrolizumab. The sample consisted of 1,558 patients [944 men (60.6%) and 614 women (39.4%)], mean (SD) age was 60.0 years (14.0). For individuals with BRAF WT and BRAF V600E/K-mutant melanoma, the objective response rate was 39.8% and 34.3%, 4-year PFS rate was 22.9% and 19.8%, and 4-year overall survival rate was 37.5% and 35.1%, respectively.
